Five-Day Antibiotic Course Noninferior for Pediatric Febrile UTI
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 26, 2023 -- For young children with febrile urinary tract infection (fUTI), a five-day amoxicillin-clavulanate course is noninferior to a 10-day course for recurrence of UTI within 30 days after completion of therapy, according to a study published online Dec. 26 in Pediatrics.
Giovanni Montini, M.D., from Ospedale Maggiore Policlinico in Milano, Italy, and colleagues conducted a multicenter, randomized, controlled trial involving children aged 3 months to 5 years with a noncomplicated fUTI to assess the noninferiority (5 percent threshold) of a five- versus 10-day antibiotic course. A total of 142 children were randomly assigned to receive amoxicillin-clavulanate 50 + 7.12 mg/kg/day orally in three divided doses for five or 10 days (72 and 70 children, respectively). The recurrence of a UTI within 30 days after completion of therapy was examined as the primary end point.
The researchers found that the recurrence rate within 30 days of the end of therapy was 2.8 and 14.3 percent, respectively, in the short and standard groups (difference, −11.51 percent). The recurrence rate of fUTI within 30 days from the end of therapy was 1.4 and 5.7 percent in the short and standard groups, respectively.
"In this study, a five-day treatment with oral amoxicillin-clavulanic acid of an acute episode of fUTI was not inferior to a 10-day course, in terms of clinical cure rates, recurrence of infection within 30 days from the end of therapy, adverse events, and development of antibiotic resistance," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and...
Obstructive Sleep Apnea Linked to Bladder Pain/Interstitial Cystitis
THURSDAY, March 7, 2024 -- Obstructive sleep apnea (OSA) seems to be associated with bladder pain syndrome/interstitial cystitis (BPS/IC) in women, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.